These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 20054671)
21. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. Akhgari A; Sadeghi F; Garekani HA Int J Pharm; 2006 Aug; 320(1-2):137-42. PubMed ID: 16782290 [TBL] [Abstract][Full Text] [Related]
22. Effect of the molecular size of carboxymethylcellulose and some polymers on the sustained release of theophylline from a hydrophilic matrix. Emeje MO; Kunle OO; Ofoefule SI Acta Pharm; 2006 Sep; 56(3):325-35. PubMed ID: 19831281 [TBL] [Abstract][Full Text] [Related]
23. Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules. Ozgüney I; Ertan G; Güneri T Farmaco; 2004 Jul; 59(7):549-55. PubMed ID: 15231431 [TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery. Moustafine RI; Margulis EB; Sibgatullina LF; Kemenova VA; Van den Mooter G Eur J Pharm Biopharm; 2008 Sep; 70(1):215-25. PubMed ID: 18691856 [TBL] [Abstract][Full Text] [Related]
25. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride. Baviskar D; Sharma R; Jain D Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739 [TBL] [Abstract][Full Text] [Related]
26. Achieving gastroresistance without coating: Formulation of capsule shells from enteric polymers. Barbosa JAC; Al-Kauraishi MM; Smith AM; Conway BR; Merchant HA Eur J Pharm Biopharm; 2019 Nov; 144():174-179. PubMed ID: 31541663 [TBL] [Abstract][Full Text] [Related]
27. Coatings of Eudragit® RL and L-55 Blends: Investigations on the Drug Release Mechanism. Wulff R; Leopold CS AAPS PharmSciTech; 2016 Apr; 17(2):493-503. PubMed ID: 26265188 [TBL] [Abstract][Full Text] [Related]
28. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline. Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450 [TBL] [Abstract][Full Text] [Related]
29. A novel electrostatic dry coating process for enteric coating of tablets with Eudragit® L 100-55. Qiao M; Zhang L; Ma Y; Zhu J; Xiao W Eur J Pharm Biopharm; 2013 Feb; 83(2):293-300. PubMed ID: 23183445 [TBL] [Abstract][Full Text] [Related]
30. Near-infrared spectroscopic analysis of the breaking force of extended-release matrix tablets prepared by roller-compaction: influence of plasticizer levels and sintering temperature. Dave VS; Fahmy RM; Hoag SW Drug Dev Ind Pharm; 2015 Jun; 41(6):898-905. PubMed ID: 24785574 [TBL] [Abstract][Full Text] [Related]
31. Design and in vitro/in vivo evaluation of sustained-release floating tablets of itopride hydrochloride. Ahmed SM; Ahmed Ali A; Ali AM; Hassan OA Drug Des Devel Ther; 2016; 10():4061-4071. PubMed ID: 28008229 [TBL] [Abstract][Full Text] [Related]
33. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Khan MZ; Stedul HP; Kurjaković N Drug Dev Ind Pharm; 2000 May; 26(5):549-54. PubMed ID: 10789067 [TBL] [Abstract][Full Text] [Related]
34. Sustained release enteric coated tablets of pantoprazole: formulation, in vitro and in vivo evaluation. Wilson B; Babubhai PP; Sajeev MS; Jenita JL; Priyadarshini SR Acta Pharm; 2013 Mar; 63(1):131-40. PubMed ID: 23482318 [TBL] [Abstract][Full Text] [Related]
35. Preparation and characterization of controlled release matrices based on novel seaweed interpolyelectrolyte complexes. Prado HJ; Matulewicz MC; Bonelli PR; Cukierman AL Int J Pharm; 2012 Jun; 429(1-2):12-21. PubMed ID: 22433798 [TBL] [Abstract][Full Text] [Related]
36. Polymers with pH-dependent solubility: possibility of use in the formulation of gastroresistant and controlled-release matrix tablets. Palmieri GF; Michelini S; Di Martino P; Martelli S Drug Dev Ind Pharm; 2000 Aug; 26(8):837-45. PubMed ID: 10900540 [TBL] [Abstract][Full Text] [Related]
37. Improved drug delivery to the lower intestinal tract with tablets compression-coated with enteric/nonenteric polymer powder blends. Rujivipat S; Bodmeier R Eur J Pharm Biopharm; 2010 Nov; 76(3):486-92. PubMed ID: 20868750 [TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of ketoprofen hot-melt extruded enteric and sustained-release tablets. Yang R; Wang Y; Zheng X; Meng J; Tang X; Zhang X Drug Dev Ind Pharm; 2008 Jan; 34(1):83-9. PubMed ID: 18214759 [TBL] [Abstract][Full Text] [Related]
39. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy. Varum FJ; Hatton GB; Freire AC; Basit AW Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235 [TBL] [Abstract][Full Text] [Related]
40. Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms. Wulff R; Rappen GM; Koziolek M; Garbacz G; Leopold CS Eur J Pharm Sci; 2015 Sep; 77():246-53. PubMed ID: 26093053 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]